Head-to-head evidence
AZD3427 vs R2R01
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Relaxin receptor (RXFP1) / relaxin · full Heart Failure pipeline
AZD3427
Developed by AstraZeneca
NCT04630067 · Phase 1 · completed
This is a randomized, double-blind, placebo-controlled dose-escalation safety study. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
R2R01
Developed by River 2 Renal
NCT06264310 · Phase 2 · completed
The study randomly assigned participants to R2R01 or placebo and used blinded treatment, but only 33 participants were enrolled across four groups. Its primary endpoint was safety and tolerability, and no primary-endpoint results or statistical comparison are posted, so the trial provides limited evidence at this time.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD3427's landscape · R2R01's landscape